Proposal of the Election Committee regarding members of the Board etc. for Vitrolife AB (publ)

Proposal of the Election Committee regarding members of the Board etc. for
Vitrolife AB (publ)

The Election Committee of Vitrolife, which was appointed in accordance with the
resolution of the Annual General Meeting, consists of:
Henrik Blomquist, representing Bure Equity AB
Johan Ståhl, representing Lannebo Fonder
Martin Lewin, representing Eccenovo AB
Patrik Tigerschiöld, Chairman of the Board

The Board proposes re-election of the Board members Patrik Tigerschiöld,
Madeleine Olsson-Eriksson, Fredrik Mattsson, Maris Hartmanis and Tord Lendau and
election of the new Board member Barbro Fridén (Director of the Children's
Division at the Astrid Lindgren Children's Hospital, Karolinska University
Hospital). The Board member Semmy Rülf has declined re-election. It is proposed
that Patrik Tigerschiöld be re-elected as Chairman of the Board. 
It is proposed that Board fees of SEK 700,000 be paid, with SEK 200,000 to the
Chairman of the Board and SEK 100,000 kronor to each of the other members of the
Board. The proposal means that the total Board fee is unchanged from the
previous year. 
Furthermore, the Election Committee proposes that a new Election Committee be
set up for the Annual General Meeting of 2011. It is proposed that the Election
Committee is appointed in the same way as previously, whereby the Chairman of
the Board contacts the three largest registered shareholders or otherwise known
owners at the end of the third quarter of 2010 and asks them to appoint one
member each. The three members who are appointed and the Chairman of the Board
constitute the Election Committee. The Election Committee appoints a Chairman
internally. 
　 
For further information, please contact 
Henrik Blomquist, Chairman of the Election Committee, tel. +46 8 614 00 20
Patrik Tigerschiöld, Chairman of the Board, tel. +46 8 614 00 20

________________________________________________________________________________
________________________________________________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. 
     The Fertility product area works with nutrient solutions (media),
cryopreservation products and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to evaluate and maintain organs
outside the body order to select usable organs and keeping them in optimal
condition while waiting for transplantation. The Stem Cell Cultivation product
area works with media and instruments to enable the use and handling of stem
cells for therapeutic purposes. 
     Vitrolife today has approximately 170 employees and the company's products
are sold in more than 85 markets. The company is headquartered in Gothenburg,
Sweden, and there are subsidiaries in USA, Australia, France, Italy and Japan.
Production facilities are located in Sweden and USA. 
     The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
________________________________________________________________________________
_________________________________________________
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com.
Website: www.vitrolife.com.

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on
Tuesday March 23, 2010 at 17:15 pm CET.

This is a translation of the Swedish version of the notice. When in doubt, the
Swedish wording prevails.